Loading…
← CockpitCompetitor Analysis › 4552.T JCR Pharmaceuticals Co., Ltd.Open in the cockpit ↗

JCR Pharmaceuticals Co., Ltd.4552.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum neutral 41
Mkt cap
$379M
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$2.94M
20-day average traded
Fwd P/E
398.3×
forward earnings
ROIC−WACC
-8.9 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
71 days
28 Jan 2027
Close · JPY¥496
1D-0.8%
1W+0.6%
1M-7.1%
3M-5.7%
6M-5.0%
YTD-30.3%
1Y-19.4%
ATR %3.9%
52w lowhigh39.8% off high

What JCR Pharmaceuticals does

Employees: 985

JCR Pharmaceuticals at a glance

Size JCR Pharmaceuticals (4552.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $379M, the 1210th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥496 on 18 Nov 2026.

Performance Over six months the shares fell 5.0%, against -25.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th highest of 19 in its peer set.

Growth Revenue grew 3.0% over the last twelve months (peer median -1.1%); the operating margin is -13.8% (peer median -2.2%).

Valuation It trades at 398.3× forward earnings against a peer median of 16.3× (most expensive of 5).

Capital Return on invested capital runs 8.9 points below its cost of capital (5.0% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 20264552.T 99Peer median 75
Six months, rebased to 100: JCR Pharmaceuticals against the median of its 20 peers (local-currency closes).

JCR Pharmaceuticals financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥38.9B¥40.3B¥33.1B¥42.9B¥34.3B
Revenue growth—+22%-23%+25%—
Gross profit¥27.3B¥30.1B¥22.0B¥31.3B¥25.5B
EBITDA-¥3.20B¥2.99B-¥3.04B¥10.7B¥6.97B
Net income-¥3.40B¥2.18B-¥4.46B¥5.51B¥3.77B
Free cash flown/a-¥11.6B-¥15.4B¥7.79B-¥13.2B
Capital expendituren/a¥11.6B¥9.67B¥2.10B¥8.56B
Total debt¥63.7B¥54.0B¥38.3B¥23.4B¥22.9B

Quarterly statements and history in the cockpit →

JCR Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%IRD688399002868PBYI459230053442CSPRYAVTX002872300452MPLT301111219A005690301089300636UNICHEMLAB4552.T6-month return →1-month return →
Up and to the right = strong over both horizons. JCR Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×PBYI3004520056903006364552.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JCR Pharmaceuticals is the large dot.

JCR Pharmaceuticals competitors and peer comparison

How JCR Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JCR Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure4552.TPeer medianRank in peer set
1-month return-7.1%-14.0%7th highest of 20
6-month return-5.0%-25.1%7th highest of 19
Distance from 52-week high-39.8%-42.0%11th highest of 21
Revenue growth (TTM)+3.0%-1.1%9th highest of 18
Operating margin-13.8%-2.2%8th lowest of 19
Forward P/E398.3×16.3×most expensive of 5
ROIC minus cost of capital-8.9 pp-5.1 pp6th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%398.3×n/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%n/an/an/a
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%n/an/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%n/an/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%19.0×0.1%+0.3%
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%n/a20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%n/an/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%n/an/an/a
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%n/an/an/a
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%n/a22.2%-15.7%
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%13.6×-5.5%+12.2%
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%n/an/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%n/an/an/a
Heartseed 219A.TJapan$392M+53%+197%9%n/a46.5%+73.2%
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%8.2×-7.9%+24.8%
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%n/an/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%52.7×14.9%+13.7%
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%n/an/an/a

Questions

Which companies are JCR Pharmaceuticals's closest peers?
The cockpit's peer set: Opus Genetics (IRD), Jiangsu Bioperfectus Technologies (688399.SS), Lifecome Biochemistry (002868.SZ), Puma Biotechnology (PBYI), SanBio (4592.T), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Shukra Pharmaceuticals (SHUKRAPHAR.NS), iX Biopharma (42C.SI).
Is JCR Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 398.3× against a peer median of 16.3×, most expensive of 5 in its peer set.
How has JCR Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -5.0% against -25.1% for the median peer; over one year -19.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.